2017年第一季度制药行业的重大交易。
Notable deals in the pharmaceutical industry in the first quarter of 2017.
作者信息
Cruces E
机构信息
Clarivate Analytics, Barcelona, Spain.
出版信息
Drugs Today (Barc). 2017 Jun;53(6):357-365. doi: 10.1358/dot.2017.53.6.2662982.
During the first quarter of 2017, Cortellis Competitive Intelligence had 1,073 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This meant a slight increase on the last quarter (1,022) and a similar volume on the same quarter for the previous 1 year (1,141). However, this quarter showed a significant augment in deals worth more than USD 0.5 billion on the last quarter (17 vs. 12). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
在2017年第一季度，科睿唯安竞争情报（Cortellis Competitive Intelligence）新增了1073笔新交易，作为其对药品许可活动持续跟踪报道的一部分。这意味着较上一季度（1022笔）略有增长，与前一年同一季度的交易量（1141笔）相近。然而，本季度价值超过5亿美元的交易较上一季度有显著增加（从12笔增至17笔）。本文将重点介绍本季度达成的一些最具价值和最值得关注的交易，以及一些交易活跃机构的部分交易情况。还将介绍具有重要意义的里程碑、期权和终止交易的最新情况，以及对下一季度药品许可活动的早期展望。
Zotero 插件